Biogen Inc said on Wednesday it was diverting part of its budget and resources for blockbuster multiple sclerosis drug Tecfidera towards a potential launch of its Alzheimer's disease drug, aducanumab.
Pfizer Inc said on Friday it could file in late November for U.S. authorization of the COVID-19 vaccine it is developing, suggesting that a vaccine could potentially be available in the United States by the end of the year. | Video
Walgreens Boots Alliance Inc on Thursday forecast a return to growth in profit next year, pinning hopes on shoppers coming back to its stores in the second half of the year after a safe and effective coronavirus vaccine is developed.
Oct 15 Walgreens Boots Alliance Inc on
Thursday forecast a return to growth in profit next year,
pinning hopes on shoppers coming back to its stores in the
second half of the year after a safe and effective coronavirus
vaccine is developed.
Johnson & Johnson said on Tuesday it would take a few days at least to hear from a safety monitoring panel about its review of the company's late-stage COVID-19 vaccine trial after announcing that the large study had been paused due to an unexplained illness in one participant. | Video
Johnson & Johnson said on Tuesday it would take at least a few days for an independent safety panel to evaluate an unexplained illness of a study participant that led to a pause in the company's COVID-19 vaccine trial. | Video
NEW YORK The U.S. government expects to be able to provide at no cost more than 1 million doses of antibody treatments for COVID-19 similar to the one President Donald Trump received to treat his illness, according to a top U.S. health official on Friday.
Eli Lilly and Co on Wednesday said it applied for U.S. emergency use authorization (EUA) for its experimental COVID-19 antibody treatment and plans to pursue a similar approval for a dual antibody therapy next month after it produced promising data.
The U.S. Food and Drug Administration told coronavirus vaccine developers on Tuesday it wants at least two months of safety data before authorizing emergency use, a requirement that would likely push any U.S. vaccine availability past the Nov. 3 presidential election.